UICC believes that partnering with our members and the private sector can deliver high-impact results. Read on to find out how UICC and its partners are working together and connecting for global impact.
UICC is proud to partner with some of the largest cancer organisations in the world, including the National Cancer Institute, the Centre for Disease Control, the World Cancer Research Fund International, the American Cancer Society, the Swiss Cancer League - to name a few. Their continued support and engagement have been fundamental to help us achieve tremendous results at the global and political levels - for the benefit of the global cancer community.
We are excited to continue to partner with these strong and influential cancer societies over the coming years and to welcome new partners from around the world.
“The Swiss Cancer League is proud to have joined forces with UICC as it has enabled us to network with the global cancer community, access capacity building opportunities, and advocate to drive progress for cancer control.”
“At Astellas we have a social responsibility to improve access to better health for patients worldwide, and UICC has provided us with an international platform to achieve this. Being a Vanguard Partner has been extremely valuable in positioning us as a leading player in the global fight against cancer.”
“UICC is fortunate to have such a strong leadership and network of members. As we are working to build relationships with UICC members, the World Cancer Congress offers an unprecedented opportunity to network with them and discuss areas of common interest.”
“The World Cancer Congress is an important opportunity for the global cancer community to drive change in cancer care through collaborations and community engagement. At Pfizer, we are committed to our continued efforts to work with UICC, and a diverse group of stakeholders in the cancer community, to continue to fight cancer on a global scale.”
“World Cancer Day is a special day because people striving to end cancer unite and they recommit to this extremely important cause. By working together, we can all make a difference. We are proud to support World Cancer Day and help people with cancer to live better, longer lives.”
“Fondation Philanthropia is delighted to work with our UICC partners to address cancer globally. Investing in the organisation’s capacity building plans means that we are impacting more cancer organisations around the world and helping them improve their skills and competencies. We represent a range of philanthropists committed to tackling the staggering burden of cancer and are convinced that new approaches should be championed, and consider capacity to be a critical component.”
“We are delighted to announce Hernâni as the winner of the Astellas Oncology C3 prize at the World Cancer Leaders’ Summit as this was the perfect opportunity to showcase his work and connect with leading cancer control experts from across the globe.”
“There is an urgent need for multilevel stakeholder partnerships in response to a growing global cancer crisis. NCI is proudly partnering with UICC to support cities with populations of more than 1 million improve their capacity to address prevention, screening, diagnosis, and treatment at the city level.”
“C/Can 2025 serves as a turning point for the global cancer community. For the first time, an international coalition of multisectoral organisations has been established to work at the city level to improve cancer treatment and care. Stemming from the radiotherapy industry, Varian is pleased to serve as a founding member of this outstanding initiative. It is important for all sectors to support city governments to show the world that together we can tackle this disease.”
“The ambition of UICC to have cancer treatment solutions in all cities with a population of over 1 million people by 2025 is truly visionary. This, coupled with their track record of delivering with excellence, makes UPMC proud to be involved as a partner. Through initiatives such as these, we are on our way to reach the global target of reducing cancer’s burden by 25% by 2025.”